Global Aluminum-Nickel Catalyst Market: Industry Size, Analysis, Technology advancement, Overview, Growth, Share and Forecasts

MarketResearchReports.Biz adds “Global Aluminum-Nickel Catalyst Market 2016 Share, Size, Trends and Forecast to 2021 Market Research Report” reports to its database. This report provides a strategic analysis of the Aluminum-Nickel Catalyst market and the growth estimates for the forecasted period.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of global aluminium nickel catalyst market on the basis of Type Activated and Non-Activated; By End-Users Refinery Industry, Chemical Industry and Others; By Region - North America, Europe, APAC, ROW; By Country U.S., Canada, U.K., Germany, France, Netherlands, India, China, Japan, Brazil

Global Aluminum Nickel Catalyst Market is forecasted to grow at a CAGR of 4.34% during 2016 2021. The strong growth of aluminum nickel catalyst market is attributed to the increased demand by the refinery industry, chemicals as well as the polymers industry. The aluminum nickel catalyst market is expected to register a substantial growth in the near future. Rising prominence of Green Chemistry, increased demand for advanced catalytic technologies as well as reactivation of spent raney nickel catalyst are some of the emerging trends in the global aluminum nickel catalyst market.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/906619

Refinery Industry holds the major percentage share in the total market by end-user and is projected to display a faster growth in the future. Among the regions, Asia-Pacific holds the largest market share mainly due to increasing population, higher disposable incomes, and the growing automotive and construction industry.

According to Azoth Analytics research report, Global Aluminum-Nickel Catalyst Market By Type, By End-Use Industry, By Region, By Country: Opportunities and Forecasts (2016-2021) (By Type Activated, Non-Activated; By End-User Industry Refinery, Chemical, Others; By Region - North America, Europe, APAC, ROW; By Country U.S., Canada, U.K., Germany, France, Netherlands, India, China, Japan, Brazil)

Scope of the Report

The report provides coverage by Type, by End-Users, by Region and by Country:

By Type

• Activated
• Non-Activated

By End-Users

• Refinery Industry
• Chemical Industry
• Others

By Region

• North America
• Europe
• Asia-Pacific
• ROW

By Country

• US
• Canada
• France
• U.K.
• Germany
• France
• Netherlands
• China
• India
• Japan
• Brazil

Report Highlights:

• Primary Research: Interviews conducted with key management people to gain quality responses and deeper insights.
• Secondary Research: Data and insights from industry associations, annual reports, company presentations, premium journals and internal database.
• Actual Period: Historical and current market sizing (2012-2015)
• Forecast Period: Projected market sizing (2016E-2021F)
• Companies Covered: BASF SE, Hangzhou Jiali metal Technology Co.,Ltd., Evonik In-dustries AG, Vineeth Chemicals, Johnson Matthey, Haldor Topsoe A/S, W. R. Grace & Co., Axens, Sigma Aldrich, Alfa-Aesar
• Strategic Recommendations

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Tungsten Market: By Applications - Hard Metals, Mill Products, Steel and Alloys, Chemicals

MarketResearchReports.Biz adds “Global Tungsten Market 2016 Share, Size, Trends and Forecast to 2021 Market Research Report” reports to its database. This report provides a strategic analysis of the Tungsten market and the growth estimates for the forecasted period.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of global tungsten market on the basis of End-Use Application (Hard Metals, Mill Products, Steel and Alloys, Chemicals & Others), By End-User Industries (Automotive, Mining, Construction, Oil & Gas, Aerospace & Defense and Medical), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., Germany, China, India, Japan, Brazil and Saudi Arabia).

Global Tungsten Market is forecasted to grow at a CAGR of 4.25% during 2016 2021. Strong growth in tungsten market is driven by the surging demand for downstream tungsten products in varied end-user sectors including automotive, industrial engineering, energy, and aviation. Apart from that, the uncovering of the wide range of applications in allied industries like medical, defense and electric and electronic, has been impelling growth in the tungsten market.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/943744

Although, hard metals hold the major percentage share in the total tungsten market in the present, consumption of tungsten for mill products is projected to display a faster growth in the future owing to the increasing application in high growth electronic and construction industries. Regionally, tungsten demand growth is likely to be the fastest in the Asia Pacific region against the backdrop of economic growth in emerging markets. Developed regions of North America and Europe are expected to display a steady paced growth, mainly due to high expenditure in automotive and engineering sectors.

According to Azoth Analytics research report, Global Tungsten Market (By End-Use Application, By End-User Industries, By Region, By Country): Trends, Opportunities and Forecasts (2016-2021), market is projected to exhibit a CAGR of 4.25% during 2016 - 2021. Global Tungsten Market has been segmented on basis of End-Use Application (Hard Metals, Mill Products, Steel and Alloys, Chemicals & Others), By End-User Industries (Automotive, Mining, Construction, Oil & Gas, Aerospace & Defense and Medical), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., Germany, China, India, Japan, Brazil and Saudi Arabia).

Scope of the Report

The report provides coverage by End-Use Application, End-User Industries, By Region and By Country:

By End-Use Application

• Hard Metals
• Steel and Other Alloys
• Mill Products
• Chemical
• Other

By End-User Industries

• Automotive
• Mining
• Construction
• Oil & Gas
• Aerospace and Defense
• Medical

By Region

• North America
• Europe
• APAC
• ROW

By North America Tungsten Market

• By Hard Metals, By Finished Product Type
• By Hard Metals, By End-User Industries

By Country

• U.S
• Canada
• Germany
• U.K
• China
• India
• Japan
• Brazil
• Saudi Arabia

Report Highlights:

• Primary Research: Interviews conducted with key management people to gain quality responses and deeper insights.
• Secondary Research: Data and insights from industry associations, annual reports, company presentations, premium journals and internal database.
• Actual Period: Historical and current market sizing (2011-2015)
• Forecast Period: Projected market sizing (2016E-2021F)
• Companies Covered: Sandvik AB, Kennametal Inc., Sumitomo Electric Industries, Ltd., Nippon Tungsten Co., Ltd, NAECO, LLC., Toonney Alloy(Xiamen) Co.,Ltd., Federal Carbide Company, Buffalo Tungsten Inc.
• Srategic Recommendations

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Transcatheter Aortic Valve Replacement (TAVR) Market To Set At CAGR Of 18.30% Between 2017 – 2022

MarketResearchReports.Biz adds “Global Transcatheter Aortic Valve Replacement (TAVR) Market 2017 Share, Size, Trends and Forecast to 2022 Market Research Report” reports to its database. This report provides a strategic analysis of the Transcatheter Aortic Valve Replacement (TAVR) market and the growth estimates for the forecasted period.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Transcatheter Aortic Valve Replacement Market, on the basis of Type of Approach (Transfemoral and Transapical); By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, Germany, France, U.K., China, India, Japan, Brazil and South Africa).

Transcatheter aortic valve replacement (TAVR) has been a ground-breaking advancement in the field of interventional cardiology and cardiovascular surgery. Although, surgical aortic valve replacement is considered the standard treatment, yet 30% of patients are not considered candidates for traditional open heart surgery because of advanced age and presence of multiple comorbidities. Transcatheter aortic valve replacement offers this population a less invasive treatment option also with better outcomes. Over the recent years, the global TAVR industry has been growing rapidly mainly due to growing number of elderly population, rising awareness about minimally invasive devices, new device approvals and increasing health expenditure in developing countries.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/1064494

According to Azoth Analytics research report, “Global Transcatheter Aortic Valve Replacement Market: Analysis By Type of Approach (Transfemoral and Transapical), By Region (North America, Europe, Asia Pacific, Rest of the World), By Country (U.S., Canada, Germany, France, U.K., China, India, Japan, Brazil and South Africa): (2017-2022)” global market is projected to display a robust growth represented by a CAGR of 18.30% during 2017 – 2022, chiefly driven by large number of product approvals and launches, rising geriatric population, rapid adoption in U.S. and growing awareness about minimally invasive techniques.

Among the type of approach, transfemoral retrograde is the most common catheter-based approach and is performed in approximately 70% to 80% of the total TAVR cases, globally. Among the regions, Europe accounts for the largest regional share in the total TAVR market in 2016. However, Asia Pacific is predicted to advance at the highest rate, mainly driven by increase in healthcare expenditure coupled with growing penetration and awareness about technologically advanced heart valve therapies.

The report titled, “Global Transcatheter Aortic Valve Replacement Market: Analysis By Type of Approach (Transfemoral and Transapical), By Region (North America, Europe, Asia Pacific, Rest of the World), By Country (U.S., Canada, Germany, France, U.K., China, India, Japan, Brazil and South Africa): (2017-2022)” has covered and analysed the potential of Global Transcatheter Aortic Valve Replacement Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global transcatheter aortic valve market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Transcatheter Aortic Valve Replacement Market 
• Transcatheter Aortic Valve Replacement Market- By Transfemoral Approach
• Transcatheter Aortic Valve Replacement Market- By Transapical Approach

Regional Markets – North America, Europe, APAC, RoW (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Transcatheter Aortic Valve Replacement Market 
• Transcatheter Aortic Valve Replacement Market- By Transfemoral Approach
• Transcatheter Aortic Valve Replacement Market- By Transapical Approach

Country Analysis - US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Transcatheter Aortic Valve Replacement Market 

Other Report Highlights

• Market Dynamics – Trends, Drivers, Challenges
• Porter Five Forces Analysis
• SWOT Analysis
• Competitive Landscape
• Country Pricing and Volume Analysis
• Company Share Analysis
• Policy and Regulatory Landscape
• Company Analysis 
• Edwards Lifesciences Corporation
• Medtronic Plc
• Boston Scientific Corporation
• St. Jude Medical Inc. 
• JenaValve Technology Inc.
• Meril Life Sciences Pvt. Ltd.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Fatty Liver Disease Market volume, revenue, product price, top players, market share and growth rate

Latest industry research report on: Fatty Liver Disease Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), which may lead to inflammation (steatohepatitis) and fibrosis. It has the potential to progress to end-stage liver diseases such as cirrhosis, liver cancer and liver failure, and is also associated with numerous complications and co-morbidities, including cardiovascular and metabolic diseases. FLD can be divided into non-alcoholic FLD (NAFLD) and alcoholic FLD (AFLD), depending on the patent’s history of alcohol use.

FLD is the most common chronic liver disease in the world, and its global prevalence has increased rapidly in the past several decades. The worldwide prevalence of FLD is estimated at 20–45% in the general population, and up to 90% in obese patients. There is a broad consensus to describe the condition as the hepatic manifestation of metabolic syndrome, and it is closely associated with obesity, diabetes and dyslipidemia. NAFLD has become the main driver of the rapid growth of FLD prevalence, mainly due to the rising prevalence of obesity.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/1065937

FLD is increasingly recognized as a major global health problem. However, despite this the FLD market is still in its infancy, with no FDA-approved drugs for this indication, and only a limited number of generic drugs approved in non-US markets in recent years.

Due to the increasing health burden of FLD and the lack of therapeutic options, there is a pressing need to develop pharmacological strategies. This is especially the case for patients with steatohepatitis, who are at the greatest risk of developing cirrhosis or liver cancer, which can lead to liver failure. Due to the pathophysiological complexity of FLD and its diverse population, different therapeutic agents are likely to be needed to tackle the lipotoxicity, inflammation and fibrogenesis that drive FLD progression.

FLD has an active pipeline and first-in-class products account for a considerable proportion, which is very promising considering the level of unmet need and lack of approved treatment options. First-in-class innovation is concentrated heavily at the early drug development stages, and prominent first-in-class molecular targets include nuclear receptors, immune mediators, and molecules involved in lipid synthesis. Additionally, the first-in-class targets identified show considerable diversity, reflecting the multifaceted aspects of FLD pathophysiology.

Scope

FLD comprises a diverse patient population with significant unmet needs

• 
  
•  What is the pathophysiology of FLD?
•  What are the common co-morbidities and complications?
•  What are the most significant unmet needs within the market?

The FLD pipeline is relatively large and has a high degree of first-in-class innovation

•  Which molecule types and molecular targets are most prominent within the pipeline?
• Which first-in-class targets are most promising?
• How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?

The FLD deal landscape shows rising deal volumes and considerable investment opportunities

• Do FLD products attract high deal values?
• Which molecule types and molecular targets dominate the deals landscape?
• Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

This report will allow you to - 

• Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.
• Visualize the composition of the FLD market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.
• Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to FLD, all first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
• Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Colorectal Cancer Market volume, revenue, product price, top players, market share and growth rate

Latest industry research report on: Colorectal Cancer Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in the form of a small polyp within the colon or rectum. It rarely occurs in the absence of polyps, although can arise as a result of an inflammatory bowel disease such as Crohn’s disease or ulcerative colitis. CRC was the third most prolific oncological indication with regard to the number of new cases in the US in 2016.

The disease can be divided into two categories based on how advanced it is upon diagnosis. These are early-stage (adjuvant) CRC, which can be treated with surgery, and metastatic (advanced) CRC, which cannot. Therapeutic options differ between the two treatment settings, with therapies for adjuvant CRC aiming to prevent disease re-occurrence and those for advanced conditions aiming to slow disease progression while maintaining the patient’s quality of life.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/984797

Targeted therapies have already begun to extend the lifespan of metastatic CRC patients compared with chemotherapy-only regimens. However, there remains an unmet need to improve the efficacy of treatment options and extend survival for these patients. Additionally, an unmet need exists for patients with KRAS mutation-positive CRC, for whom certain currently marketed therapies are not recommended.

This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the CRC market, with additional focus on the late-stage pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

• How is the colorectal cancer market landscape expected to change with regard to therapeutic type, due to promising pipeline therapies?
• What are the clinical characteristics of currently approved therapies for colorectal cancer, in terms of specific safety and efficacy parameters?
• How are clinical safety and efficacy parameters linked to the key unmet needs in this indication? 
• How will current late-stage immunotherapeutics affect the colorectal cancer market, and will they be able to satisfy current unmet need with regard to effective therapy options?
• Are future product approvals likely to affect the treatment algorithm significantly?

Reasons to buy

• Understand the current clinical landscape by considering the treatment options available for earlyand late-stage disease.
• Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
• Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
• Understand the relative strengths and weaknesses of the studies used to gather these data.
• Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
• Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Cardiovascular Disorders Drug Development Market volume, revenue, product price, top players, market share and growth rate

Latest industry research report on: Cardiovascular Disorders Drug Development Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/1049123

There are over 1,200 pipeline products within the CVD therapy area. Over 50% of these products are small molecules however there is also diversification with regards to molecule types within the pipeline. In addition, the molecular targets in the pipeline are considerably diverse with a high frequency of products acting on targets related to lipid metabolism and those which act on elements of the coagulation cascade.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as PCSK9 inhibitors and direct factor Xa inhibitors.

The report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

• Which companies are the most active within the pipeline for CVD.
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication.
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies.
• What are the most important R&D milestones and data publications to have happened in this disease area.

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4

List of Tables 6

List of Figures 15

Introduction 18

Cardiovascular Disorders Report Coverage 18

Hypertension Overview 18

Dyslipidemia Overview 18

Thromboembolism Overview 18

Heart Failure Overview 18

Therapeutics Development 20

Hypertension 20

Dyslipidemia 22

Thromboembolism 24

Heart Failure 26

Therapeutics under Development by Companies 31

Hypertension 31

Dyslipidemia 35

Thromboembolism 39

Heart Failure 40

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Develop business strategies Of Antibacterial Therapies Drug Development Market

Latest industry research report on: Antibacterial Therapies Drug Development Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.

There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.

Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the bodys immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/1049122

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.

The report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

• Which companies are the most active within the pipeline for antibacterial drugs.
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication.
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies.
• What are the most important R&D milestones and data publications to have happened in this disease area.

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4

List of Tables 6

List of Figures 16

Introduction 20

GBI Research Report Coverage 20

Tuberculosis Overview 20

Pneumonia 20

Methicillin-Resistant Staphylococcus aureus (MRSA) 21

Therapeutics Development 22

Tuberculosis 22

Pneumonia 24

Methicillin-Resistant Staphylococcus aureus (MRSA) 33

Therapeutics under Development by Companies 38

Tuberculosis 38

Pneumonia 41

Methicillin-Resistant Staphylococcus aureus (MRSA) 50

Therapeutics under Investigation by Universities/Institutes 55

Tuberculosis 55

Pneumonia 57

Methicillin-Resistant Staphylococcus aureus (MRSA) 60

Pipeline Products Glance 62

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz